Key result
Rheumatology anticoagulation demands individualized drug selection balancing bleeding risks and interactions.
Why the study?
The use of anticoagulant drugs in rheumatology remains challenging due to misconceptions about hypercoagulability and drug interactions affecting anticoagulant dosing.
Answers are grounded in this paper and cite their sources.
The use of anticoagulant therapy is a part of the daily work of clinicians and a reason for fear, primarily due to the risk of bleeding. The use of anticoagulant drugs in rheumatology remains a challenge. first, a large number of clinicians consider rheumatic conditions as a hypercoagulable state, which often leads to wrong decisions. second, the use of drugs in the treatment of rheumatic diseases may be associated with an increased risk of venous thromboembolism (vte), and they can have effect on dose of anticoagulant agent. The aim of this paper is to present the properties of anticoagulant therapy through the prism of rheumatological pathology.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a review in Rheumatic diseases requiring anticoagulation. Anticoagulant therapy was evaluated. Anticoagulant therapy in rheumatology remains challenging due to bleeding risks and drug interactions, requiring individualized selection among heparins, vitamin K antagonists, and NOACs.
Synapse has enriched 10 related papers. Consider them for comparative context: